XTL Biopharmaceuticals Ltd.
Clinical-stage biopharmaceutical company developing drugs for autoimmune diseases.
XTLB | TA
Overview
Corporate Details
- ISIN(s):
- IL0010854979
- LEI:
- 529900NDDXEAPTUTXP41
- Country:
- Israel
- Address:
- 5 HaCharoshet St., 4365603 Raanana
- Website:
- https://www.xtlbio.com
- Sector:
- Manufacturing
Description
XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-11-25 19:58 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 31, 2020
|
English | 125.2 KB | ||
| 2020-11-12 18:43 |
6K: Financial results for the nine months ended September 30, 2020
|
English | 143.0 KB | ||
| 2020-11-12 18:43 |
6K: Financial results for the nine months ended September 30, 2020
|
English | 36.0 KB | ||
| 2020-08-24 18:45 |
Financial results for the six months period ended June 30, 2020
|
English | 140.0 KB | ||
| 2020-08-24 18:45 |
Financial results for the six months period ended June 30, 2020
|
English | 36.0 KB | ||
| 2020-07-07 17:22 |
results of the Extraordinary
General Meeting of shareholders of the Company, T…
|
English | 78.7 KB | ||
| 2020-07-07 17:22 |
results of the Extraordinary
General Meeting of shareholders of the Company, T…
|
English | 37.9 KB | ||
| 2020-06-30 17:23 |
Immediate Report of Meeting
|
English | 61.1 KB | ||
| 2020-05-27 18:35 |
Financial results for the quarter ended March 31, 2020.
|
English | 140.5 KB | ||
| 2020-05-27 18:35 |
Financial results for the quarter ended March 31, 2020.
|
English | 37.9 KB | ||
| 2020-05-26 19:09 |
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, …
|
English | 377.6 KB | ||
| 2020-05-26 19:09 |
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, …
|
English | 61.2 KB | ||
| 2020-05-26 15:56 |
The board of directors appointed Shlomo Shalev to serve as Chief Executive Offi…
|
English | 107.5 KB | ||
| 2020-05-26 15:56 |
The board of directors appointed Shlomo Shalev to serve as Chief Executive Offi…
|
English | 37.8 KB | ||
| 2020-03-12 23:00 |
Annual Report - Form 20-F 2019
|
English | 770.7 KB |
Automate Your Workflow. Get a real-time feed of all XTL Biopharmaceuticals Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for XTL Biopharmaceuticals Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for XTL Biopharmaceuticals Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
